MS Speaks

Multiple Sclerosis => MS - RESEARCH AND NEWS => Topic started by: agate on July 27, 2020, 02:08:41 pm

Title: (JAMA) Association of sustained immunotherapy w/disability outcomes in active SPMS
Post by: agate on July 27, 2020, 02:08:41 pm

These researchers are saying that even persons with SPMS might benefit from the disease-modifying drugs.  The study (link below) includes this statement:

Quote

Although this intraindividual variability in disease course makes any individual prognosis difficult, it also offers the possibility that MS with sufficient episodic inflammatory activity remains modifiable with immunotherapy at any stage of disease.

From JAMA Neurology (July 27, 2020), "Association of sustained immunotherapy with disability outcomes in patients with active secondary progressive multiple sclerosis":



https://bit.ly/2X1lHnI